Creative Medical Technology Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Creative Medical Technology Holdings, Inc. on February 18, 2021, reporting events occurring on February 11 and February 12, 2021. The filing details the entry into a material definitive agreement and the unregistered sale of equity securities to raise capital.
Key Financial Metrics and Transaction Details
- Capital Raised: $350,000 aggregate purchase price for 350,000 shares of Series B Preferred Stock.
- Equity Issuance: 1,500,000 shares of Common Stock issued as "Commitment Shares" to the purchaser.
- Preferred Stock Terms: Stated value of $1,200.00 per share; convertible to Common Stock at $0.05 per share (subject to adjustment).
- Dividends: 10% per annum, payable quarterly in cash or additional shares at the Company's option.
- Redemption: Company may redeem shares at $1,200 plus accrued dividends and a premium ranging from 5% to 20% depending on the timing of redemption.
- Liquidity and Debt: The filing text does not provide specific values for total debt, cash flow, or overall liquidity positions outside of this transaction.
Material Changes and Security Rights
The Company completed a private placement with BHP Capital NY, Inc. pursuant to Section 4(a)(2) of the Securities Act and Rule 506(b). A "Triggering Event" as defined in the Certificate of Designation will reduce the conversion price to $0.035. Upon liquidation or dissolution, Series B Preferred Stock holders have priority over Common Stock holders to receive $1,200 per share plus accrued dividends and unpaid fees.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard terms of the securities issued. The transaction is subject to the terms of the Securities Purchase Agreement and Certificate of Designation filed as exhibits.
Investor Verification Checklist
- Verify the definition of a "Triggering Event" in the Certificate of Designation (Exhibit 3.1) to understand dilution risks.
- Confirm the Company's ability to pay the 10% quarterly dividend in cash versus issuing additional shares.
- Review the redemption premium schedule to assess potential future cash outflows if the Company exercises its redemption option.
- Check the total outstanding share count to evaluate the dilution impact of the 1,500,000 Commitment Shares and potential conversion of Preferred Stock.